<DOC>
	<DOC>NCT02406092</DOC>
	<brief_summary>Safety Study of Rituximab in Patients with Non Hodgkin Lymphoma (DLBCL &amp; FL)</brief_summary>
	<brief_title>Safety Study of Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. Patients with specific types of Non Hodgkin lymphoma 1. Transformed lymphoma or follicular lymphoma (FL) IIIB 2. History of other malignancy that could affect compliance with the protocol or interpretation of results. This includes a malignancy that has been treated but not with curative intent, unless the malignancy has been in remission without treatment for &gt;/= 5 years prior to dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>